Trial
NCT04150692
Escalation of Daratumumab Frequency Following Biochemical Progression in Relapsed/Refractory Multiple Myeloma
Phase IIWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
Washington University School of Medicine
Collaborators
Janssen, LP
Condition
Multiple Myeloma
Intervention
Dara-SC
Why stopped
Investigator decision
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-01-24